Preview

Current Pediatrics

Advanced search

EXPERIENCE OF ALPROSTADIL APPLICATION AGAINST RAYNAUD'S SYNDROME AMONG CHILDREN

Abstract

The article provides the data on the causes and mechanisms of Raynaud's syndrome development. initial or idiopathic Raynaud's syndrome is characterized by the spasm of the digital arteries and thermoregulatory vessels of skin under the impact of the cold without any signs of vessel lesions. In the event of secondary Raynaud's syndrome, there is combination of Raynaud's syndrome with the symptoms of other diseases. Secondary raynaud's syndrome is most often associated with scleroderma systematica, systemic erythema centrifugum, other rheumatic diseases, hematologic disc orders and intake of some medications. There is also data on the opportunity to apply the synthetic medication prostaglandin е 1 — alprostadil to treat Raynaud's syndrome associated with rheumatic diseases. The given clinical example demonstrates high efficacy of alprostadil in case of the patient, suffering from scleroderma systematica and generalized Raynaud's syndrome.
Key words: children, scleroderma systematica, alprostadil, Raynaud's syndrome.

About the Authors

E.I. Alexeeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


S.I. Valieva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


K.B. Isaeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


R.М. Denisova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Ревматические болезни. Под ред. В.А. Насонова, Н.В. Бунчук. М.: Медицина. 1997.

2. Black C.M., Pereira S., McWhiter et al. Genetic susceptibility to scleroderma like syndrome in symptomatic and asymptomatic workers exposed to vinilchlorid. J. Rheum. 1986; 13: 1059–1062.

3. Малахов А.Б., Давтян В.Г., Осминина М.К, Геппе Н.А. Системная склеродермия: современные аспекты проблемы. Consilium Medicum. 2006; 8 (2): 46–52.

4. Rodnan G.P., LeRoy E.C. Vascular Abnormalaties in systemic sclerosis. In: Systemic sclerosis (scleroderma) In: Systemic sclerosis. Ed. Black C.M., Mayers A.R. New York: Gower. 1985. P. 239–241.

5. Kinlough R.L. The effect of prostaglandin E1 on platelet. Br. J. Hemol. 1970; 19: 559–571.

6. Heidrich Н. The importance of prostaglandin E1 in peripheral arterial occlusive disease. Am. J. Ther. 1997; 4: 351–352.

7. Гусева Н.Г. Простагландин Е1: результаты и перспективы применения в клинической практике. Клиническая медицина. 2001; 2: 4–9.

8. Rab Mwitz В., Schollmayer E., Weiss М. Prostaglandin E1 in heart disease: review and perspective. Am. J. Ther. 1997; 4: 353–358.

9. Гусева Н.Г. Эффективность и перспективы применения вазапростана (простагландина Е1) в ревматологии. Терапевтический архив. 2002; 74 (5): 85–88.

10. Гусева Н.Г., Алекперов Р.Т. Вазопростан при ССД. Клиническая ревматология. 1997; 4: 5–9.

11. Bilts H., Kuster W., Luders G., Wehrmoum W. Prostaglandin E1 ber progressiver systemischer sklerodermic. VaSA. 1980; 23: 138–140.

12. Покровский А.В., Дан В.Н., Чупин А.В., Калинин А.А. Применение алпростана в лечении больных с перемежающейся хромотой. Ангиология и сосудистая хирургия. 2006; 12 (2): 29–32.

13. Покровский А.В., Дан В.Н., Чупин А.В., Калинин А.А. Использование препарата Алпростан в лечении перемежающейся хромоты при атеросклеротическом поражении артерий нижних конечностей. Материалы XV международной конференции Российского общества ангиологов и сосудистых хирургов. Ангиология и сосудистая хирургия (приложение). 2005; 234–235.

14. Покровский А.В., Дан В.Н., Чупин А.В., Калинин А.А. Алпростан в лечении больных с критической ишемией нижних конечностей. Ангиология и сосудистая хирургия. 2005; 11 (1): 7–10.


Review

For citations:


Alexeeva E., Valieva S., Isaeva K., Denisova R. EXPERIENCE OF ALPROSTADIL APPLICATION AGAINST RAYNAUD'S SYNDROME AMONG CHILDREN. Current Pediatrics. 2007;6(5):128-131.

Views: 1409


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)